Abstract
To date, the efficacy of the phenylalanine hydroxylase (PAH) cofactor is proved for the treatment of both BH4-dependent hyperphenylalaninemia and phenylketonuria patients with mutations in the PAH gene. Since the patient’s response depends on the presence of residual PAH enzyme activity, it is advisable to search for mutations in the PAH gene to identify the potential responders and nonresponders to therapy. Four hundred thirty-five phenylketonuria patients from 13 regions of the Russian Federation were genotyped in order to identify responders and nonresponders to tetrahydrobiopterin (BH4) therapy. According to the results of this study, the number of probable nonresponders to the BH4 treatment exceeds 50% owing to a higher overall allelic frequency of “severe” PAH gene mutations. Responder patients with two “mild” mutations in the PAH gene were identified (1.6%).
Similar content being viewed by others
References
Blau, N., Hennermann, J.B., Langenbeck, U., and Lichter-Konecki, U., Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies, Mol. Genet. Metab., 2011, vol. 104, suppl., pp. S2—S9. doi 10.1016/j.ymgme.2011.08.017
Guttler, F., Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood, Acta Paediatr. Scand. Suppl., 1980, vol. 280, pp. 1–80.
Bernegger, C. and Blau, N., High frequency of tetrahydrobiopterin- responsiveness among hyperphenylalaninemias: a study of 1919 patients observed from 1988 to 2002, Mol. Genet. Metab., 2002, vol. 77, no. 4, pp. 304–313.
Fiege, B. and Blau, N., Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria, J. Pediatr., 2007, vol. 150, no. 6, pp. 627–630. doi 10.1016/j.jpeds.2007.02.017
Kure, S., Hou, D.C., Ohura, T., et al., Tetrahydrobiopter-in-responsive phenylalanine hydroxylase deficiency, J. Pediatr., 1999, vol. 135, no. 3, pp. 375–378.
Heintz, C., Cotton, R.G., and Blau, N., Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria, Hum. Mutat., 2013, vol. 34, no. 7, pp. 927–936. doi 10.1002/humu.22320
Dobrowolski, S.F., Heintz, C., Miller, T., et al., Molecular genetics and impact of residual in vitro phenylalanine hydroxylase activity on tetrahydrobiopterin responsiveness in Turkish PKU population, Mol. Genet. Metab., 2011, vol. 102, no. 2, pp. 116–121. doi 10.1016/j.ymgme.2010.11.158
Anichkina (Stepanova), A.A., Gavrilyuk, A.P., Tverskaya, S.M., and Polyakov, A.B., Analysis of the most common mutations in the PAH gene in patients with phenylketonuria, Med. Genet., 2003, vol. 2, no. 4, pp. 175–181.
Stepanova, A.A., Tverskaya, S.M., Zinchenko, R.A., and Polyakov, A.V., Molecular genetic study of the phenylalanine hydroxylase gene in the group of Russian phenylketonuria patients, Med. Genet., 2006, vol. 5, no. 2, pp. 32–39.
Gundorova, P., Stepanova, A.A., Shchagina, O.A., and Polyakov, A.B., Application of the new medical technologies “Detection of major PAH gene point mutations by multuplex ligase reaction” and “Detection of ten additional mutations in PAH gene by multuplex ligase reaction” in the DNA-diagnostics of phenylketonuria, Med. Genet., 2016, vol. 15, no. 2, pp. 29–36.
Blau, N., Yue, W., and Perez, B., PAHvdb. http://www.biopku.org/pah/.
Zurfluh, M.R., Zschocke, J., Lindner, M., et al., Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, Hum. Mutat., 2008, vol. 29, no. 1, pp. 167–175. doi 10.1002/humu.20637
Tighe, O., Dunican, D., O’Neill, C., et al., Genetic diversity within the R408W phenylketonuria mutation lineages in Europe, Hum. Mutat., 2003, vol. 21, no. 4, pp. 387–393.
Zschocke, J., Phenylketonuria mutations in Europe, Hum. Mutat., 2003, vol. 21, no. 4, pp. 345–356. doi 10.1002/humu.10192
Trunzo, R., Santacroce, R., D’Andrea, G., et al., Phenylalanine hydroxylase deficiency in south Italy: genotype—phenotype correlations, identification of a novel mutant PAH allele and prediction of BH4 responsiveness, Clin. Chim. Acta, 2015, vol. 450, pp. 51–55. doi 10.1016/j.cca.2015.07.014
Bayat, A., Yasmeen, S., Lund, A., et al., Mutational and phenotypical spectrum of phenylalanine hydroxylase deficiency in Denmark, Clin. Genet., 2015, vol. 90, no. 3, pp. 247–251. doi 10.1111/cge.12692
Stojiljkovic, M., Jovanovic, J., Djordjevic, M., et al., Molecular and phenotypic characteristics of patients with phenylketonuria in Serbia and Montenegro, Clin. Genet., 2006, vol. 70, no. 2, pp. 151–155.
Sterl, E., Paul, K., Paschke, E., et al., Prevalence of tetrahydrobiopterine (BH4)-responsive alleles among Austrian patients with PAH deficiency: comprehensive results from molecular analysis in 147 patients, J. Inherit. Metab. Dis., 2013, vol. 36, no. 1, pp. 7–13. doi 10.1007/s10545-012-9485-y
Groselj, U., Tansek, M.Z., Kovac, J., et al., Five novel mutations and two large deletions in a population analysis of the phenylalanine hydroxylase gene, Mol. Genet. Metab., 2012, vol. 106, no. 2, pp. 142–148. doi 10.1016/j.ymgme.2012.03.015
Zschocke, J., Preusse, A., Sarnavka, V., et al., The molecular basis of phenylalanine hydroxylase deficiency in Croatia, Hum. Mutat., 2003, vol. 21, no. 4, p. 399. doi 10.1002/humu.9115
Gemperle-Britschgi, C., Iorgulescu, D., Mager, M.A., et al., A novel common large genomic deletion and two new missense mutations identified in the Romanian phenylketonuria population, Gene, 2016, vol. 576, no. 1, part 1, pp. 182–188.
Polak, E., Ficek, A., Radvanszky, J., et al., Phenylalanine hydroxylase deficiency in the Slovak population: genotype—phenotype correlations and genotype-based predictions of BH4-responsiveness, Gene, 2013, vol. 526, no. 2, pp. 347–355. doi 10.1016/j.gene.2013. 05.057
Dobrowolski, S.F., Borski, K., Ellingson, C.C., et al., A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria patients in western Poland and implications for treatment with 6R tetrahydrobiopterin, J. Hum. Genet., 2009, vol. 54, no. 6, pp. 335–339. doi 10.1038/jhg.2009.37
Kasnauskiene, J., Giannattasio, S., Lattanzio, P., et al., The molecular basis of phenylketonuria in Lithuania, Hum. Mutat., 2003, vol. 21, no. 4, p. 398. doi 10.1002/humu.9113
Pronina, N., Giannattasio, S., Lattanzio, P., et al., The molecular basis of phenylketonuria in Latvia, Hum. Mutat., 2003, vol. 21, no. 4, pp. 398–399. doi 10.1002/humu.9114
Gundorova, P., Stepanova, A.A., Makaov, A.Kh., et al., Mutation spectrum of the PAH gene in phenylketonuria patients in the Karachay-Cherkess Republic (Russia), Russ. J. Genet., 2016, vol. 52, no. 12, pp. 1282–1290. doi 10.1134/S1022795416110041
Levy, H.L., Milanowski, A., Chakrapani, A., et al., Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study, Lancet, 2007, vol. 370, no. 9586, pp. 504–510. doi 10.1016/s0140- 6736(07)61234-3
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © P. Gundorova, A.A. Stepanova, T.V. Bushueva, E.Yu. Belyashova, R.A. Zinchenko, S.S. Amelina, S.I. Kutsev, A.V. Polyakov, 2017, published in Genetika, 2017, Vol. 53, No. 6, pp. 732–739.
Rights and permissions
About this article
Cite this article
Gundorova, P., Stepanova, A.A., Bushueva, T.V. et al. Genotyping of patients with phenylketonuria from different regions of Russia for determining BH4 responsiveness. Russ J Genet 53, 712–718 (2017). https://doi.org/10.1134/S1022795417060060
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1022795417060060